Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 4, 2010Gut

Managing HBV in patients with impaired immunity

View Full Paper
Ask AI
Bookmark
Share

Authors

KWKarsten WursthornHWHeiner WedemeyerMMM.P. Manns

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wursthorn et al. (2010) studied this question.

synapsesocial.com/papers/69ece370b9d00a98d60723edhttps://doi.org/10.1136/gut.2009.195834
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy2000 · 225 citations
  2. 2Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients2005 · 23 citations
  3. 3Lamivudine therapy in patients undergoing liver transplantation for hepatitis b virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immu1999 · 114 citations
  4. 4Liver Transplantation in European Patients with the Hepatitis B Surface Antigen1993 · 1,054 citations
  5. 5Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy2001 · 173 citations